CBD Metabolite Differences Did Not Establish Higher Parent-Drug Exposure
A sex difference in a CBD metabolite is not automatically a sex difference in CBD itself. A small pharmacokinetic analysis found higher exposure to the carboxy metabolite in women while parent-CBD comparisons did not show significant differences.
An analysis of previously collected samples
Twelve healthy volunteers, six women and six men, received oral CBD at 750 mg twice daily for three days and a single dose on day four. Investigators analyzed plasma CBD, 7-hydroxy-CBD and 7-carboxy-CBD using samples from an earlier drug-interaction experiment.
These were human plasma measurements under a short, high-dose regimen. The analysis was not a trial assigning different treatment doses by sex, nor a study of intoxication or driving performance.
Different analytes supported different conclusions
The investigators reported higher body-weight-normalized peak concentration and area under the curve for 7-carboxy-CBD in women. Parent CBD peak concentration and exposure did not show corresponding significant sex differences. Race and body-mass-index comparisons also did not establish significant differences in the reported main parameters.
The carboxy metabolite was described as inactive, whereas 7-hydroxy-CBD is an active metabolite. This biological distinction further limits any assumption that higher carboxy-metabolite exposure necessarily means stronger clinical effects from the parent drug.
Why the sample matters
Six participants per sex provide limited precision for subgroup analysis. The samples arose from a study also involving methylphenidate, which must remain part of the experimental context. Several explanatory mechanisms discussed by the authors were hypotheses rather than demonstrated causes.
Clinical interpretation must distinguish parent drug, active metabolite and terminal metabolite before translating a concentration difference into benefit or risk. This study motivates larger pharmacokinetic work; it does not establish that all women require a particular CBD dose reduction.
Related: Interpreting cannabinoid concentrations and functional effects.
Primary research
Pharmacokinetic Variability of Oral Cannabidiol and Its Major Metabolites after Short-Term High-Dose Exposure in Healthy Subjects. Medical Cannabis and Cannabinoids (2024).
